• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大规模注册研究中应用薄壁持久聚合物或早期代更厚壁涂覆生物可吸收聚合物药物洗脱支架经皮治疗无保护左主干病变

Percutaneous Treatment of Unprotected Left Main Disease With Thin-Strut Durable-Polymer or Early Generation Thicker-Strutted and Coated Bioabsorbable-Polymer Drug-Eluting Stents in a Large-Scale Registry.

机构信息

Division of Cardiology, UCLA Medical Center, Los Angeles, CA, United States of America.

Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea.

出版信息

Cardiovasc Revasc Med. 2021 Nov;32:43-49. doi: 10.1016/j.carrev.2020.12.034. Epub 2020 Dec 31.

DOI:10.1016/j.carrev.2020.12.034
PMID:33446435
Abstract

BACKGROUND

The ideal drug-eluting stent (DES) for the treatment of unprotected left main coronary artery (ULMCA) is unknown. We compared percutaneous coronary intervention (PCI) using durable polymers versus early-generation, thicker strutted and coated bioabsorbable polymers for ULMCA disease.

METHODS

Patients who underwent ULMCA PCI (893 patients) from April 2008 to November 2014 were identified from the Grand-DES registry. The primary end point was 3-year target lesion failure (TLF) after propensity score matching.

RESULTS

The final analysis included 754 patients (84.4%) and 139 patients (15.6%) in the durable and bioabsorbable polymer group, respectively. The groups differed significantly in lesion and procedural characteristics. Propensity score-matched analysis revealed a trend toward a lower 3-year TLF in the durable polymer group (log rank p=0.071). Independent predictors of 3-year TLF were chronic kidney disease, presentation with acute myocardial infarction, and a two-stenting technique for ULMCA lesions. Definite/probable stent thrombosis rates at 3-years were low in both groups (0.8% vs. 0.7%, p=0.925).

CONCLUSIONS

The safety of ULCMA PCI was excellent, and durable and bioabsorbable polymer DES provided similar clinical outcomes at 3-year follow-up. Landmark analysis revealed that the durable polymer group had a lower TLF rate from 9 months. Further studies are needed to confirm these results.

摘要

背景

用于治疗无保护左主干冠状动脉(ULMCA)的理想药物洗脱支架(DES)尚不清楚。我们比较了使用耐用聚合物与早期、更厚的支撑和涂层可生物吸收聚合物治疗 ULMCA 疾病的经皮冠状动脉介入治疗(PCI)。

方法

从 2008 年 4 月至 2014 年 11 月,从 Grand-DES 注册中心确定了接受 ULMCA PCI 的患者(893 例患者)。主要终点是倾向性评分匹配后 3 年的靶病变失败(TLF)。

结果

最终分析包括 754 例患者(84.4%)和 139 例患者(15.6%)分别在耐用聚合物组和可生物吸收聚合物组。两组在病变和手术特征方面存在显著差异。倾向性评分匹配分析显示,耐用聚合物组 3 年 TLF 发生率呈下降趋势(对数秩检验 p=0.071)。3 年 TLF 的独立预测因素为慢性肾脏病、急性心肌梗死发作和 ULMCA 病变的双支架技术。两组 3 年明确/可能的支架血栓形成率均较低(0.8%比 0.7%,p=0.925)。

结论

ULMCA PCI 的安全性非常好,耐用聚合物和可生物吸收聚合物 DES 在 3 年随访时提供了相似的临床结果。里程碑分析显示,耐用聚合物组从 9 个月开始 TLF 率较低。需要进一步的研究来证实这些结果。

相似文献

1
Percutaneous Treatment of Unprotected Left Main Disease With Thin-Strut Durable-Polymer or Early Generation Thicker-Strutted and Coated Bioabsorbable-Polymer Drug-Eluting Stents in a Large-Scale Registry.大规模注册研究中应用薄壁持久聚合物或早期代更厚壁涂覆生物可吸收聚合物药物洗脱支架经皮治疗无保护左主干病变
Cardiovasc Revasc Med. 2021 Nov;32:43-49. doi: 10.1016/j.carrev.2020.12.034. Epub 2020 Dec 31.
2
Bioresorbable polymer-coated thin strut sirolimus-eluting stent vs durable polymer-coated everolimus-eluting stent in daily clinical practice: Propensity matched one-year results from interventional cardiology network registry.日常临床实践中生物可吸收聚合物涂层薄支架西罗莫司洗脱支架与耐用聚合物涂层依维莫司洗脱支架的比较:介入心脏病学网络登记的倾向匹配一年结果
Catheter Cardiovasc Interv. 2019 Jun 1;93(7):E362-E368. doi: 10.1002/ccd.27919. Epub 2018 Oct 8.
3
Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.薄、极薄或超薄支架,生物可降解或耐用聚合物涂层药物洗脱支架:BIO-RESORT 的 3 年结果。
JACC Cardiovasc Interv. 2019 Sep 9;12(17):1650-1660. doi: 10.1016/j.jcin.2019.04.054. Epub 2019 Aug 14.
4
Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies).可吸收聚合物西罗莫司洗脱支架(MiStent)与耐用聚合物依维莫司洗脱支架(Xience)的比较(来自DESSOLVE I/II和ISAR-TEST-4研究)。
Am J Cardiol. 2016 Feb 15;117(4):532-538. doi: 10.1016/j.amjcard.2015.11.044. Epub 2015 Dec 7.
5
A propensity score-matched comparison of biodegradable polymer vs second-generation durable polymer drug-eluting stents in a real-world population.在真实世界人群中,可生物降解聚合物与第二代耐用聚合物药物洗脱支架的倾向性评分匹配比较。
Cardiovasc Ther. 2018 Apr;36(2). doi: 10.1111/1755-5922.12319. Epub 2018 Jan 30.
6
First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).首例人体生物可吸收聚合物涂层依维莫司洗脱支架的评估:DESOLVE I 试验(载有依维莫司和生物可吸收聚合物的 DES 治疗原发性冠状动脉病变患者)的影像学和临床结果。
JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.
7
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.与含有不可降解聚合物的西罗莫司洗脱支架相比,含可生物降解聚合物的比伐卢定洗脱支架在冠状动脉疾病患者中具有更好的安全性和降低支架血栓形成的风险:LEADERS(雷帕霉素从不可降解到可降解涂层支架洗脱)随机、非劣效性试验的最终 5 年报告。
JACC Cardiovasc Interv. 2013 Aug;6(8):777-89. doi: 10.1016/j.jcin.2013.04.011.
8
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.生物可降解聚合物西罗莫司洗脱支架与耐久性聚合物依维莫司洗脱支架在 ST 段抬高型心肌梗死患者中的比较(BIOSTEMI):一项单盲、前瞻性、随机优效性试验。
Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X. Epub 2019 Sep 2.
9
1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents.全人群患者接受 2 款生物可吸收聚合物涂层依维莫司洗脱支架治疗 1 年的临床结局:COMBO 和 Ultrathin-Strut Orsiro 支架倾向性评分匹配比较。
JACC Cardiovasc Interv. 2020 Apr 13;13(7):820-830. doi: 10.1016/j.jcin.2019.11.023.
10
Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.药物洗脱支架置入治疗无保护左主干冠状动脉疾病后,冠状动脉解剖结构和支架技术对长期预后的影响。
JACC Cardiovasc Interv. 2014 Jan;7(1):29-36. doi: 10.1016/j.jcin.2013.08.013. Epub 2013 Dec 11.